Galeterone metabolism in castration resistant prostate cancer

Zhenfei Li¹, Mohammad Alyamani², Jianneng Li², Nima Sharifi²,³,⁴ *

¹ Shanghai Institute of Biochemistry and Cell Biology, CAS, China
² Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
³ Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
⁴ Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
*Correspondence: Nima Sharifi

Background: Steroidal medicine like abiraterone is used for castration resistant prostate cancer (CRPC) treatment. Previously we have reported that abiraterone is recognized by steroidogenic enzymes to generate several new metabolites which would affect the efficacy of abiraterone. It is not clear whether the novel metabolism of abiraterone is unique to abiraterone or common to all other steroidogenic medicines. So we investigated the metabolism of galeterone, a steroidal CYP17A1 inhibitor under evaluation in a clinical trial for CRPC treatment.

Methods: We used LC-MS to detect potential galeterone metabolites in cell medium and mouse serum. To evaluate the function of galeterone metabolites, we used HPLC to detect androgen metabolism and qPCR to investigate AR target gene expression. Xenograft in mouse model is utilized to investigate the function of galeterone metabolites in vivo.

Results: We found that galeterone is metabolized by 3βHSD to D4-galeterone (D4G), which is further converted by steroid-5α-reductase (SRD5A) to 3-keto-5α-galeterone (5αG), 3α-OH-5α-galeterone, and 3β-OH-5α-galeterone in prostate cancer cells. In vivo galeterone is also converted to other three corresponding 5β-reduced metabolites. D4G inhibits steroidogenesis and suppresses AR protein stability, AR target gene expression, and xenograft growth comparably with galeterone, and further conversion by SRD5A leads to loss of several activities that inhibit the androgen axis that may compromise the clinical efficacy of galeterone.

Conclusions: Together, our findings define a critical metabolic class effect of steroidal drugs with a Δ⁵ 3β-hydroxyl structure. The function of galeterone metabolites is different from that of abiraterone metabolites.

Conflict of Interest: There is no conflict of interest.

Funding Acknowledgements: This work is supported in part by funding from 2015 Prostate Cancer Foundation Young Investigator Award and the US Army Medical Research and Materiel Command (PC121382).